Navigation Links
KemPharm's KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Date:8/26/2013

NORTH LIBERTY, Iowa, Aug. 26, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced positive results from one of several clinical and non-clinical studies that the company is performing in preparation for its New Drug Application (NDA) for KP201 (benzhydrocodone and acetaminophen), which the company anticipates filing in the second quarter of 2014.

In a two-stage, single and multiple-dose, oral pharmacokinetic (PK) study in 26 healthy volunteers, KP201 effectively released and achieved steady-state plasma concentrations of hydrocodone, its active metabolite hydromorphone and acetaminophen.  The data also confirmed that KP201 was metabolized completely and that no systemic prodrug exposure was observed in any subject at any time point during the study.  KP201 was also shown to be safe and well tolerated by the opioid-naive volunteers in the study.

Sven Guenther, Ph.D., Vice President of Research at KemPharm, commented, "The results of this study confirm two key benefits of KP201 and of our novel prodrug approach to abuse deterrence: 1) single and multiple doses of KP201 tablets release hydrocodone effectively only upon oral administration, and 2) the prodrug itself is metabolized completely and does not reach the systemic circulation, even at the maximum daily dose.  In the coming months, we anticipate reporting additional bioavailability and bioequivalence data that we expect will affirm the unique physicochemical and pharmacological attributes of KP201."

Travis C. Mickle, Ph.D., President and CEO of KemPharm, added, "This data set is an important milestone for KemPharm as it marks one of several clinical and non-clinical studies of KP201 that we expect to complete in preparation for the filing of an NDA in the second quarter of 2014.  As the safety, tolerability and PK performance of KP201 is further established, we believe the prodrug has the potential to fulfill a significant therapeutic and market need as a first-in-class opioid-based prodrug that possesses the ability to reduce abuse potential and opioid-induced constipation."

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

319-665-2575

info@kempharm.com

 

 

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

jdrumm@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
3. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
4. Sectra Demonstrates Radiation Dose Monitoring System at AHRA and AAPM Meetings
5. New Data From Partners Center For Connected Health Demonstrates Wireless Mobile Technology Improves Patient Engagement, Outcomes
6. New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR
7. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
8. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
9. New Cardiac Electrical Biomarker Featured In Johns Hopkins Abstract Demonstrates Strong Correlation To High Sensitivity Troponin To Rule Out Acute Myocardial Ischemic Injury
10. MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT
11. West Health Institute demonstrates research advances in medical device interoperability to lower the cost of health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... Palm City, FL (PRWEB) , ... June 24, 2016 , ... ... and inflammation common after venous procedures, dermaka cream can be incorporated into the post-surgical ... peels, and minor surgical procedures. , dermaka cream is very effective for bruising ...
(Date:6/24/2016)... New York (PRWEB) , ... June 24, 2016 , ... ... marijuana patients optimize the ingestion of their medication by matching users with high quality ... users to compare pieces with no commitment. , Inhale was founded by two brothers, ...
Breaking Medicine News(10 mins):